Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia - Results of a phase-II trial

Annals of Hematology

Volumn 77, Issue 5, 1998, Pages 225-229

  Schneller, F ^a   Schuler, M ^b   Schumacher, K ^d   Thaler, J ^c   Peschel, C ^a   Huber, C ^b   Aulitzky, W ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Blast crisis; Chronic myelogenous leukemia; Cytarabine; Idarubicin; Interferon

Indexed keywords

ALPHA2B INTERFERON; BUSULFAN; CYTARABINE; ETOPOSIDE; GAMMA INTERFERON; HYDROXYUREA; IDARUBICIN; MITHRAMYCIN; VINDESINE;

ADULT; ARTICLE; BLAST CELL CRISIS; BONE MARROW APLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0031771434     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050447     Document Type: Article

References (23)

1. Allan NC, Richards SM, Shepherd PCA (1995) UK medical research council randomised, multicentre trial of interferon alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 345:1392-1397
2. Anger B, Heimpel H (1989) Daunomycin, cytosine-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML. Blut 58:299-301
3. Aulitzky WE, Peschel C, Schneller F, Huber C (1995) Biotherapy of chronic myelogenous leukemia. Ann Hematol 70:113-120
4. Berman E, Raymond V, Gee T, Kempin SJ, Andreeff M, Gulati S et al (1989) Idarubicin in acute leukemia: results of studies at Memorial Sloan Kettering Cancer Center. Semin Oncol 16 [Suppl 2]: 30-34
5. Carella AM, Podesta M, Frassoni F, Raffo MR, Pollicardo N, Pungolino E, Vimercati R, Sessarego M, Parodi C, Rabitti C, Ferrero R, Benvenuto F, et al (1993) Collection of "normal" blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 12:267-271
6. Carella AM, Podesta M, Frassoni F, Pungolino E, Pollicardo N, Raffo MR, Ferrero R, Benvenuto F, Figari O, Giordano D, et al (1993) Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. Stem Cells Dayt 11:67-72
7. Ernst TJ, Rosenthal DS, Griffin JD, et al (1988) Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol 11:623-626
8. Guilhot F, Chastang G, Michallet M, Guerci A, Harousseau J, Maloisel F, Bouabdallah R, et al (1997) Interferon alfa 2b with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223-229
9. Herzig RH, Phillips GL, Lazarus HM, et al (1985) High-dose cytarabine for the treatment of blastic phase chronic myelogenous leukemia. Cancer Treat Rep 69:881-883
10. Iacoboni SJ, Plunkett W, Kantarjian HM, et al (1986) High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4:1079-1088
11. Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alpha 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825
12. Kantarjian HM, Keating MJ, Talpaz M, et al (1987) Chronic myelogenous leukemia in blastic crisis: analysis of 242 patients. Am J Med 83:445-454
13. Kantarjian HM, Walters RS, Keating MJ, et al (1988) Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62:672-676
14. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M (1992) Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon alpha and low dose cytarabine. J Clin Oncol 10:772-778
15. Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A (1992) Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin. high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 10:398-405
16. Kantarjian HM, Deisseroth A, Kurzrock R, Estroy Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82:691-703
17. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M (1996) Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87:3069-3081
18. Lambertenghi-Deliliers G, Annaloro C, Cortellaro M, Pozzoli M, Oriani A, Polli EE (1991) Idarubicin in blastic crisis of chronic myelogenous leukemia. Haematologica (Pavia) 76:406-408
19. Lazzarino M, Morra E, Brusamolino E, Alessandrino EP, Orlandi E, Pagnucco G, Castagnola C, Bernasconi P, Merante S, Bonfichi M, et al (1991) Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea. Hematol Oncol 9:299-305
20. Matulonis UA, Griffin JD, Canellos GP (1994) Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol 45:283-287
21. Reiffers J, Trouette R, Marit G, Montastruc M, Faberes C, Cony-Makhoul P, David B, Bourdeau MJ, Bilhou-Nabera C, Lacombe F, et al (1991) Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol 77:339-345
22. Sales V, Rojo J, Collazo J, Lagunas E, Aguilar E, Albisua L (1991) Chronic granulocytic leukemia in blastic crisis. Prognostic factors. In Vivo 5:281-285
23. Speth PA, Minderman H, Haanen C (1989) Idarubicin versus daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol 16 [Suppl 2]: 2-9